Wednesday, November 16
Evening Registration and Welcome Reception

Thursday, November 17
SESSION I: Update on Clinical Trials in Colorectal Cancer
SESSION II: Update on Clinical Trials in Ovarian Cancer
SESSION III: Keynote Lecture, Debate & Best Abstracts Presentations
  • Keynote Lecture: Animal Models - What Can They Tell Us About the Management of Peritoneal Metastases?
  • Debate: Adjuvant HIPEC Is Superior/Inferior To Second-Look Surgery With HIPEC In High Risk Primary Colorectal Cancer For Peritoneal Metastases
  • Presentation of Best Abstracts (1-4)
SESSION IV: Debate & Case Presentations with Panel of Experts
  • Debate: CRS and HIPEC is/is not the Standard of Care for Selected Patients with Colorectal Peritoneal Metastases in the United States
  • Case Presentations: Prevention and Treatment of Peritoneal Metastases from Colorectal Cancer
Evening Networking Welcome Reception

Visit www.psogi2016.com for the most updated program information

Friday, November 18
Registration and Meet the Professor Breakfast Breakouts
SESSION V: Update on Clinical Trials in Gastric Cancer
SESSION VI: Update on National/International Peritoneal Metastases Registries
SESSION VII: Best Abstracts Presentations & Case Presentations
  • Presentation of Best Abstracts (5-8)
  • Case Presentations: Peritoneal Metastases from Gastric Cancer
SESSION VIII: Keynote Lecture, Debate & Case Presentations
  • Keynote Lecture: Current Treatment Options for Management of Gastric Cancer with Peritoneal Metastases
  • Debate: Recurrent Ovarian Cancer – CRS Aand HIPEC is/ is not a Reasonable Treatment Option Now in Selected Patients
  • Case Presentations: CRS and HIPEC for Unusual Diseases
SESSION IX: Keynote Lecture, Debate & Case Presentations
  • Keynote Lecture: Progress in the Management of Primary and Recurrent Ovarian Cancer in Cordoba, Spain
  • Debate: Pharmacology and Clinical Data Show/Do Not Show, that Mitomycin C not 5-FU and High Dose Oxaliplatin is the Current Standard of Care for Peritoneal Metastases from Colon Cancer
  • Case Presentations: The Prevention and Treatment of Peritoneal Metastases from Ovarian Cancer
Evening Congress Banquet with Historical Documentary:
30 Years of Progress in Treating Peritoneal Metastases

Saturday, November 19
Meet the Professor Breakfast Breakouts
SESSION X: New Technologies to Optimize Management of Peritoneal Surface Malignancy
  • Keynote Lecture: Genomic Medicine as it Involves Peritoneal Metastases
  • Keynote Lecture: Bidirectional Adjuvant Normothermic Chemotherapy (BANC) Long-Term for Management of Ovarian Cancer
  • Keynote Lecture: 90% of the Adverse Outcomes Occur in 10% of Patients. Can We Identify the High Risk Groups?
  • Case Presentations: Prevention and Treatment of Peritoneal Metastases from Appendiceal Cancer

Looking Ahead to the 2018 Congress in Paris
POST-CONFERENCE SATELLITE PROGRAMS
Pharmacology of Chemotherapy Treatments for Peritoneal Metastases: Optimizing and Augmenting HIPEC
Peritoneal Metastases Imaging

Meet the Professor Breakfast Sessions
On Friday, November 18 and Saturday, November 19, PSOGI 2016 will host 10 morning sessions that will include a continental breakfast. Each session will highlight a specific topic in a small group setting with international renowned leaders in the field. A complete listing of session titles and chairs can be found on www.psogi2016.com.
Course Description

In the past decade, the treatment of peritoneal metastases has gained interest from oncologic communities around the world. During the 1990’s, the first pioneering centers began treating patients with hyperthermic intraperitoneal chemotherapy (HIPEC). Prior to HIPEC, patients were treated with palliative support and only guaranteed a few months to live. Today, if a patient with peritoneal metastases is provided with proper treatment, the survival increases to an average of several years and improved outcomes are reported every day.

The mission of the 10th International Congress on Peritoneal Surface Malignancies (PSOGI 2016) is to provide clinical and scientific information on peritoneal surface malignancies and to create awareness regarding innovative treatments that will improve the quality of life for patients. This two and a half day conference is carefully balanced to cover the wide range of topics on peritoneal metastases.

CME Accreditation

MedStar Georgetown University Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

MedStar Georgetown University Medical Center designates this live activity for a maximum of 25.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

- Utilize available data to determine optimal treatment options including cytoreduction surgery plus HIPEC for patients with peritoneal metastases (colorectal, gastric cancer, ovarian cancer, appendiceal cancer, peritoneal mesothelioma)
- List, classify and utilize prognostic quantitative indicators to select patients who will most likely benefit from cytoreductive surgery with HIPEC
- Utilize the appropriate clinical pathways, patient protocols, and surgical procedures as recommended by a panel of international experts to optimize patient care
- Evaluate the potential efficacy of drugs for use in intraperitoneal or intravenous administrations in the treatment of peritoneal metastases with special emphasis on chemotherapy treatments used in the operating room
- Improve patient selection, surgical technique and management and standardized HIPEC regiments which will result in improved patient outcomes
- Identify patients at high risk for carcinomatosis or with low volume disease at the time of primary cancer

Target Audience

This conference is intended for surgical and medical oncologists, surgical oncology nurses, surgical technicians, perfusionists, gastroenterologists, gynecologists, pharmacologists, pathologists, and other healthcare professionals interested in peritoneal surface oncology.

Registration Information

Early Bird Registration Fees (NOW through April 29, 2016)

- $500 – Physicians
- $350 – Advanced Practice Clinicians
- $350 – Allied Health Professionals

April 30, 2016 through November 16, 2016

- $700 – Physicians
- $550 – Advanced Practice Clinicians
- $550 – Allied Health Professionals

Satellite Meeting: Scientific Research

- $150 – Physicians
- $100 – Advanced Practice Clinicians
- $100 – Allied Health Professionals

An additional $100 will be added to Onsite Registrations November 17-19

Venue Information

Omni Shoreham Hotel
2500 Calvert Street, NW Washington, DC 20007

Room Block Rate: $239 night plus applicable tax

Please call Omni Reservations at 1-800-THE-OMNI (1-800-843-6664) or 202-234-0700 to book your room today! Reservations can also be made online by visiting www.psogi2016.com.

When making reservations by phone, please indicate that you are a part of the “10th International Congress on Peritoneal Surface Malignancies Group”